Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,182,830 papers from all fields of science
Search
Sign In
Create Free Account
30 ACTUAT umeclidinium 0.0625 MG/ACTUAT Dry Powder Inhaler [Incruse]
Known as:
Incruse Ellipta (umeclidinium 62.5 MCG) per ACTUAT Dry Powder Inhaler, 30 ACTUAT
, Incruse Ellipta 62.5 MCG/INHAL Dry Powder Inhaler, 30 Blisters
, UMECLIDINIUM BROMIDE 62.5 ug ORAL AEROSOL, POWDER [Incruse Ellipta]_#1
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
7 relations
Broader (1)
30 ACTUAT umeclidinium 0.0625 MG/ACTUAT Dry Powder Inhaler
Dry Powder Inhaler
Incruse
Lactose Monohydrate
Magnesium stearate
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Umeclidinium (Incruse Ellipta) for COPD.
R. Durigan
,
Valerie Niedermier
The Medical letter on drugs and therapeutics
2017
Corpus ID: 7190915
Umeclidinium is an easy-to-use, once-daily, well-tolerated, and relatively low-cost anti-cholinergic agent for maintenance…
Expand
Review
2017
Review
2017
Umeclidinium (Incruse Ellipta) for COPD.
R. Durigan
,
Valerie Niedermier
American Family Physician
2017
Corpus ID: 8599476
Umeclidinium is a relatively safe medication with few systemic adverse effects. As with aclidinium (Tudorza Pressair…
Expand
2014
2014
Once-daily treatment approved for COPD
T. Walker
2014
Corpus ID: 70552219
FDA approved umeclidinium (Incruse Ellipta, GlaxoSmithKline) once-daily anticholinergic for long-term maintenance treatment of…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE